{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Health Affairs This Week","title":"New Alzheimer's Drug Approval Expands Treatment Options — and Creates Coverage Questions","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/53eddd04\"></iframe>","width":"100%","height":180,"duration":901,"description":"Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack to the program to discuss FDA's recent approval of an Alzheimer's treatment drug, Lilly’s Kisunla, how private insurers and Medicare may cover the drug, and the emerging new class of drugs surrounding Alzheimer's treatment.\nWe announced the winner for our You're A Health Policy Wonk If... contest this week!\nUntil July 20, we are having a flash sale on Health Affairs Insider membership. Use the code HealthWonkLife for $30 off the normal Insider price.\n\nCheck out our Request For Abstracts page for the April 2025 theme issue focusing on Food, Nutrition, and Health.\n\nRelated Articles:\nApproval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment by Peter Loftus and Joseph Walker (Wall Street Journal)\nPress Release: Lilly's Kisunla Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease","thumbnail_url":"https://img.transistorcdn.com/1yTEmrg3NcfwPvygDcOosqdCKJnotdzHk5P0Oq8y-us/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzE2NjA3LzE2MDY4/MzkyNjUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}